Dimension Therapeutics Announces Appointments Of Renowned Thought Leaders To Its Scientific Advisory Committee And Clinical Advisory Boards

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dimension Therapeutics, Inc. (“Dimension” or the “Company”), a leading rare disease company advancing novel, liver-directed treatments for diverse genetic disorders, today announced that it has expanded its Scientific Advisory Committee (“SAC”) with the appointments of Ian Alexander, M.B.B.S., Ph.D., of the Sydney Children’s Hospitals Network, and Nicola Longo, M.D., Ph.D., of the University of Utah. Drs. Alexander and Longo join existing members of Dimension’s SAC, including Chair James M. Wilson, M.D., Ph.D., of the University of Pennsylvania, Terence R. Flotte, M.D., of the University of Massachusetts Medical School, and Emil D. Kakkis, M.D., Ph.D., CEO of Ultragenyx Pharmaceuticals. In addition, Mark L. Batshaw, M.D., of Children's National Medical Center, will head the company’s Clinical Advisory Board (CAB) for urea cycle disorders, and David A. Weinstein, M.D., M.M.Sc., of the University of Florida, will head Dimension’s CAB for glycogen storage disease type Ia (GSDIa).

Help employers find you! Check out all the jobs and post your resume.

Back to news